• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Clin Med . Circulating Osteopontin Levels and Outcomes in Patients Hospitalized for COVID-19

tetano

Editor, Senior Moderator
J Clin Med


. 2021 Aug 30;10(17):3907.
doi: 10.3390/jcm10173907.
Circulating Osteopontin Levels and Outcomes in Patients Hospitalized for COVID-19


Salim S Hayek[SUP] 1 [/SUP], Christoph Roderburg[SUP] 2 [/SUP], Pennelope Blakely[SUP] 1 [/SUP], Christopher Launius[SUP] 1 [/SUP], Jesper Eugen-Olsen[SUP] 3 [/SUP], Frank Tacke[SUP] 4 [/SUP], Sofia Ktena[SUP] 5 [/SUP], Verena Keitel[SUP] 2 [/SUP], Mark Luedde[SUP] 6 [/SUP], Evangelos J Giamarellos-Bourboulis[SUP] 5 [/SUP], Tom Luedde[SUP] 2 [/SUP], Sven H Loosen[SUP] 2 [/SUP]



Affiliations

Abstract

Background: Severe coronavirus disease 2019 (COVID-19) is the result of a hyper-inflammatory reaction to the severe acute respiratory syndrome coronavirus 2. The biomarkers of inflammation have been used to risk-stratify patients with COVID-19. Osteopontin (OPN) is an integrin-binding glyco-phosphoprotein involved in the modulation of leukocyte activation; its levels are associated with worse outcomes in patients with sepsis. Whether OPN levels predict outcomes in COVID-19 is unknown.
Methods: We measured OPN levels in serum of 341 hospitalized COVID-19 patients collected within 48 h from admission. We characterized the determinants of OPN levels and examined their association with in-hospital outcomes; notably death, need for mechanical ventilation, and need for renal replacement therapy (RRT) and as a composite outcome. The risk discrimination ability of OPN was compared with other inflammatory biomarkers.
Results: Patients with COVID-19 (mean age 60, 61.9% male, 27.0% blacks) had significantly higher levels of serum OPN compared to healthy volunteers (96.63 vs. 16.56 ng/mL, p < 0.001). Overall, 104 patients required mechanical ventilation, 35 needed dialysis, and 53 died during their hospitalization. In multivariable analyses, OPN levels ≥140.66 ng/mL (third tertile) were associated with a 3.5 × (95%CI 1.44-8.27) increase in the odds of death, and 4.9 × (95%CI 2.48-9.80) increase in the odds of requiring mechanical ventilation. There was no association between OPN and need for RRT. Finally, OPN levels in the upper tertile turned out as an independent prognostic factor of event-free survival with respect to the composite endpoint.
Conclusion: Higher OPN levels are associated with increased odds of death and mechanical ventilation in patients with COVID-19, however, their utility in triage is questionable.

Keywords: CRP; OPN; PCT; SARS-CoV-2; coronavirus disease 2019; death; mechanical ventilation; outcomes; procalcitonin; renal replacement therapy; risk prediction.
 
Back
Top Bottom